SCHEMBL753915

SCHEMBL753915

Cc1n[c]cc(Nc2nccs2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAPK1 P28482 1/20 0.35
ACP1 P24666 2/20 0.35
NPC1 O15118 6/20 0.34
RAB9A P51151 6/20 0.34
ALDH1A1 P00352 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
PPARG P37231 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
PKM P14618 1/20 0.34
CSF1R P07333 1/20 0.34
LTK P29376 1/20 0.34
MAPK8 P45983 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15219307 0.76 PLA2G7 (0.43) PLA2G7SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL5888996 0.74 POLB (0.43) PLA2G7SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2066542 0.72 KMT2A (0.40) PLA2G7SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL750473 0.70 KMT2A (0.46) SMN1; SMN2MAPTKMT2AMEN1LMNA
SCHEMBL753408 0.70 KDM4E (0.36) SMN1; SMN2KMT2AMEN1MAPK1NPC1
SCHEMBL751265 0.69 GSK3A (0.40) ACP1CDK9CDK5CLK4SRC
SCHEMBL1369210 0.69 ALDH1A1 (0.50) PLA2G7SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL750965 0.68
SCHEMBL14319790 0.68 RAB9A (0.56) PLA2G7SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL2066178 0.66 KMT2A (0.52) PLA2G7SMN1; SMN2MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PLA2G7 1915/4885SMN1; SMN2 3999/4885MAPT 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.